Health and Fitness Health and Fitness
Mon, June 7, 2010
[ 01:01 AM ] - Market Wire
Randomized Phase III Study Comparing REVLIMID® P .. (MPR) Compared to Autologous Stem Cell Transplant
[ 01:01 AM ] - Market Wire
Illumina Announces Purchase of HiSeqa" 2000 Units by the Broad Institute
[ 01:01 AM ] - Market Wire
In occasione della?incontro della?ASCO viene pres .. MID® in pazienti affetti da linfoma diffuso a gr
[ 01:01 AM ] - Market Wire
Beurteilung von REVLIMID® bei Patienten mit diff .. omen vom Keimzentrumstyp (GCB) oder anderer Typen
[ 01:01 AM ] - Market Wire
valuation de REVLIMID®chez les patients atteints .. s grandes cellules B de ph©notype GCB ou non-GCB
[ 12:18 AM ] - Market Wire
Presentati in occasione dell'incontro dell'ASCO i .. a combinazione REVLIMID® e Rituxan® per il Linf
[ 12:18 AM ] - Market Wire
La pr©sentation orale l'ASCO d'une ©tude interg .. 4) ©value le traitement ininterrompu au REVLIMID
[ 12:18 AM ] - Market Wire
In occasione della?ASCO vengono presentati i dati .. omalidomide in pazienti affetti da mieloma multip
[ 12:18 AM ] - Market Wire
Daten von Studie ber Pomalidomid bei Patienten mi .. efraktrem multiplem Myelom auf der ASCO vorgelegt
[ 12:18 AM ] - Market Wire
Presentan datos del estudio de pomalidomida en pacientes con mieloma mltiple refractario en ASCO
[ 12:18 AM ] - Market Wire
Pr©sentation l'ASCO des donn©es d'une ©tude su .. ment des patients atteints de my©lome multiple r
[ 12:18 AM ] - Market Wire
Pr©sentation, lors du congrs annuel de l'ASCO, d .. on du REVLIMID® et du Rituxan® pour le traiteme
[ 12:18 AM ] - Market Wire
Results from an Ongoing Phase I/II Trial of Oral INCB7839 Presented at ASCO
[ 12:18 AM ] - Market Wire
At ASCO, Oral Presentation from Intergroupe Franc .. ase III Study (IFM 2005 02) Evaluating Continuous
Sun, June 6, 2010
[ 11:27 PM ] - Market Wire
Pieris AG Appoints Chief Scientific Officer
Sat, June 5, 2010
[ 09:40 AM ] - Market Wire
Allos Therapeutics Reports New Data Demonstrating .. re Correlated with Prolonged Survival in Patients
[ 09:40 AM ] - Market Wire
Interim Positive Results From Phase 2b Brain Canc .. F-04948568 or CDX-110) Presented at 46th Annual A
[ 09:40 AM ] - Market Wire
Biogen Idec 2010 Annual Shareholder Meeting Webcast
[ 08:38 AM ] - Market Wire
Bio-Path Holdings Signs Equity Financing Deal
[ 08:38 AM ] - Market Wire
Wright Medical Group, Inc. to Participate in The Jefferies 2010 Global Life Sciences Conference
[ 08:38 AM ] - Market Wire
Results of Phase 3 ABRAXANE® Combination Trial I .. ng Cancer Show 31 Percent Improvement In Response
[ 08:38 AM ] - Market Wire
Evaluation of REVLIMID® in Patients with Either .. B Diffuse Large B-Cell Lymphoma Presented at ASCO
[ 08:38 AM ] - Market Wire
Data from Combination of REVLIMID® and Rituxan® .. B-Cell Non-Hodgkina?s Lymphoma Presented at ASCO
[ 07:36 AM ] - Market Wire
ImmunoGen, Inc. Announces Presentation of Clinical Data for Trastuzumab-DM1 at ASCO Annual Meeting
[ 07:35 AM ] - Market Wire
Teriflunomide in Adjunct to Interferon Beta Signi .. Improved Outcomes of Multiple Sclerosis Patients
[ 06:34 AM ] - Market Wire
AVEO Pharmaceuticals Initiates Phase 2 Clinical T .. SCH 900105 (AV-299) in Non-Small Cell Lung Cancer
[ 06:34 AM ] - Market Wire
LecTec Corporation Announces Shareholders Meeting to be Held September 22, 2010
[ 06:34 AM ] - Market Wire
CORRECTINGand REPLACINGLakeland Industries to Rep .. and Hold Conference Call on Friday, June 11, 2010
Fri, June 4, 2010
[ 03:20 PM ] - Market Wire
Emergent BioSolutions Announces Appointment of Marvin White to the Companya?s Board of Directors
[ 03:20 PM ] - Market Wire
CombinatoRx Announces Date of Its 2010 Annual Meeting of Stockholders

CombinatoRx Announces Date of Its 2010 Annual Meeting of Stockholders


Published on 2010-06-04 18:20:52 - Market Wire
  Print publication without navigation


CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that it currently plans to hold its 2010 Annual Meeting of Stockholders on September 8, 2010 at 8:30 a.m. Eastern Time, at its offices located at 245 First Street, Third Floor, Cambridge, Massachusetts 02142. Stockholders of record as of July 12, 2010 are entitled to notice of and to vote at the 2010 Annual Meeting of Stockholders.

About CombinatoRx

CombinatoRx, Incorporated (CRXX) develops novel drug candidates with a focus on the treatment of pain and inflammation. The company applies its combination drug discovery capabilities and its selective ion-channel modulation platform to generate innovative therapeutics. To learn more about CombinatoRx, please visit [ www.combinatorx.com ].

(c) 2010 CombinatoRx, Incorporated. All rights reserved.

Contributing Sources